NKGN: NKGen Biotech, Inc. Stock

by  •  • Comments Off on NKGN: NKGen Biotech, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 23.98
Enterprise Value ($M) 23.98
Book Value ($M) 0.00
Book Value / Share 0.00
Price / Book n/a
NCAV ($M) 0.00
NCAV / Share 0.00
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -5.35
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio n/a
Current Ratio n/a

Balance Sheet (mrq) ($M)
Current Assets 0.00
Assets 0.00
Liabilities 0.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
4 days ago 13G Pathstone Family Office, Llc 7.91
02-14 13G/A Meteora Capital, LLC 7.84
08-22 13G CFIC-2015 NV Family Investments, LLC
2024-02-07 13G/A Adage Capital Partners Gp, L.l.c. 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-09-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REP
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-03 182,751 547,292 33.39
2025-02-28 16,795 289,138 5.81
2025-02-27 42,217 326,540 12.93
2025-02-26 136,732 788,010 17.35

(click for more detail)

Similar Companies
NAMS – NewAmsterdam Pharma Company N.V. NEUP – Neuphoria Therapeutics Inc.
NGNE – Neurogene Inc. NRIX – Nurix Therapeutics, Inc.
NTLA – Intellia Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io